Core Viewpoint - Berry Genomics (000710.SZ) has announced that its subsidiary, Hangzhou Berry Health and Technology Co., Ltd., has received the medical device registration certificate from the National Medical Products Administration (NMPA) for its third-generation sequencing instrument, Sequel?IICNDx, marking it as the first third-generation sequencing platform approved for clinical use globally [1] Group 1 - The Sequel?IICNDx instrument enables rapid implementation of third-generation sequencing solutions in local clinical laboratories, facilitating "multi-use" and "mixed operation" capabilities [1] - The approval of the Sequel?IICNDx is expected to reduce sample waiting times, accelerate report cycles, and enhance the quality and level of in-hospital services [1] - Berry Genomics has achieved full self-production of third-generation sequencing detection reagents and local deployment of an intelligent report interpretation system [1] Group 2 - The company provides comprehensive localized construction services for clinical processes, including sample collection and extraction, library construction, high-throughput sequencing, data analysis and interpretation, and report management [1]

证券代码：000710 证券简称：贝瑞基因 公告编号：2025-060 成都市贝瑞和康基因技术股份有限公司 关于全资子公司三代基因测序仪Sequel®IICNDx 获得医疗器械注册证的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 三代基因测序仪Sequel® II CNDx ，是全球首款获准应用于临床的三代基因 测序平台，该测序仪的获批使三代测序解决方案可快速落地临床机构本地实验室， 能真正实现"一机多用""混合上机"，进而减少样本等待时间、加速报告周期、 提升院内服务质量与水平。截至目前，贝瑞基因已完全实现三代测序配套检测试 剂的自主生产和智能化解读报告系统的本地部署交付，可进一步为临床提供从样 本采集及提取、文库构建、高通量测序、数据分析解读到报告管理的全流程本地 化建设服务。 Sequel® II CNDx临床获批后，不仅助力临床进一步完善出生缺陷防控体系、 显著提升复杂单基因病检测能力，更推动国产技术成果加速迈向全球。贝瑞基因 将持续深化三代测序技术的临床应用，通过优化AI算法与完善本地化部署方案， 进一步降低技术门槛，让更多家庭享受到更精准、 ...

格隆汇10月31日丨贝瑞基因(000710.SZ)公布，全资子公司杭州贝瑞和康基因诊断技术有限公司的三代 基因测序仪Sequel?IICNDx于近日正式获得国家药品监督管理局（NMPA）颁发的医疗器械注册证（注 册证编号：国械注准20253222085）。三代基因测序仪Sequel?IICNDx，是全球首款获准应用于临床的三 代基因测序平台，该测序仪的获批使三代测序解决方案可快速落地临床机构本地实验室，能真正实 现"一机多用""混合上机"，进而减少样本等待时间、加速报告周期、提升院内服务质量与水平。截至目 前，贝瑞基因已完全实现三代测序配套检测试剂的自主生产和智能化解读报告系统的本地部署交付，可 进一步为临床提供从样本采集及提取、文库构建、高通量测序、数据分析解读到报告管理的全流程本地 化建设服务。 ...

每经AI快讯，10月31日，贝瑞基因（000710）(000710.SZ)公告称，全资子公司杭州贝瑞和康基因诊断 技术有限公司的三代基因测序仪Sequel IICNDx近日获得国家药品监督管理局颁发的医疗器械注册证。 三代基因测序仪Sequel II CNDx，是全球首款获准应用于临床的三代基因测序平台。截至目前，贝瑞基 因已完全实现三代测序配套检测试剂的自主生产和智能化解读报告系统的本地部署交付。 ...

Core Viewpoint - Berry Genomics announced that its wholly-owned subsidiary, Hangzhou Berry Genomics and Health Technology Co., Ltd., has received a medical device registration certificate from the National Medical Products Administration for its third-generation sequencer, Sequel® II CNDx, making it the first third-generation sequencing platform approved for clinical use globally [1] Group 1 - The Sequel® II CNDx is the world's first third-generation sequencing platform approved for clinical application [1] - Berry Genomics has achieved full self-production of third-generation sequencing detection reagents and the local deployment of an intelligent report interpretation system [1]

Core Viewpoint - The stock price of Berry Genomics has shown significant fluctuations, with a year-to-date increase of 55.15%, but a recent decline over the past 60 days of 10.45% [2][3]. Group 1: Stock Performance - As of October 31, Berry Genomics' stock price rose by 2.02% to 13.11 CNY per share, with a trading volume of 1.45 billion CNY and a market capitalization of 46.35 billion CNY [1]. - The stock has appeared on the trading leaderboard 8 times this year, with the most recent net buy of 22.37 million CNY on March 11 [2]. - The stock has experienced a 2.42% increase over the last 5 trading days and a 0.85% increase over the last 20 trading days [2]. Group 2: Financial Performance - For the period from January to September 2025, Berry Genomics reported a revenue of 686 million CNY, a year-on-year decrease of 16.65%, and a net profit loss of 52.56 million CNY, a decline of 606.13% [3]. - The company has not distributed any dividends in the last three years, with a total payout of 16.20 million CNY since its A-share listing [4]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 5.09% to 64,700, while the average number of circulating shares per person increased by 5.37% to 5,092 shares [3]. - The seventh largest circulating shareholder is a medical device ETF, which holds 1.5268 million shares as a new shareholder [4]. Group 4: Business Overview - Berry Genomics, established on April 14, 1997, specializes in high-throughput sequencing technology-based genetic testing, with its main revenue sources being reagent sales (45.74%), medical testing services (31.24%), and basic research services (18.33%) [2]. - The company operates within the pharmaceutical and biotechnology sector, specifically in medical services and diagnostic services [2].

Group 1 - The core viewpoint of the article is that Berry Genomics (000710.SZ) reported a decline in revenue and incurred a net loss for the first three quarters of 2025 [1] Group 2 - For the first three quarters, the company achieved an operating income of 686 million yuan, representing a year-on-year decrease of 16.65% [1] - The net loss attributable to shareholders of the listed company was 52.5637 million yuan [1] - The net loss attributable to shareholders after deducting non-recurring gains and losses was 53.7914 million yuan [1]

Core Insights - Berry Genomics is a leading company in the domestic gene sequencing field, established in April 1997 and listed on the Shenzhen Stock Exchange [1] Financial Performance - For Q3 2025, Berry Genomics reported revenue of 686 million yuan, ranking 5th in the industry, significantly lower than the top competitor, Dian Diagnostics, which had revenue of 7.566 billion yuan [2] - The revenue breakdown includes reagent sales at 205 million yuan (45.74%), medical testing services at 140 million yuan (31.24%), basic research services at 82.017 million yuan (18.33%), equipment sales at 15.562 million yuan (3.48%), and other services at 5.39 million yuan (1.20%) [2] - The net profit for the same period was -50.422 million yuan, ranking 4th in the industry, with the industry leader, Dian Diagnostics, reporting a net profit of 1.82 billion yuan [2] Financial Ratios - As of Q3 2025, Berry Genomics had a debt-to-asset ratio of 29.63%, which is lower than the industry average of 30.88% [3] - The gross profit margin for Q3 2025 was 47.75%, higher than the industry average of 35.76% [3] Executive Compensation - The chairman and general manager, Gao Yang, received a salary of 1.22 million yuan, a slight decrease from the previous year [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 5.09% to 64,700, while the average number of circulating A-shares held per shareholder increased by 5.37% to 5,092.33 [5]

Core Viewpoint - Berry Genomics (000710) reported a significant decline in both revenue and net profit for Q3 2025, indicating potential challenges in its business operations [1] Financial Performance - The company achieved a revenue of 238 million yuan in Q3 2025, representing a year-on-year decrease of 12.06% [1] - The net profit for the same period was -25.32 million yuan, reflecting a substantial year-on-year decline of 2355.45% [1]

格隆汇10月30日丨贝瑞基因(000710.SZ)发布公告，2025年前三季度，实现营业收入6.86亿元，同比减少 16.65%；归属于上市公司股东的净利润-5256.37万元，归属于上市公司股东的扣除非经常性损益的净利 润-5379.14万元，基本每股收益-0.1487元。 ...